Oramed Pharmaceuticals’ (ORMP) “Buy” Rating Reaffirmed at B. Riley
Oramed Pharmaceuticals (NASDAQ:ORMP)‘s stock had its “buy” rating reissued by investment analysts at B. Riley in a research report issued to clients and investors on Monday, MarketBeat reports. They currently have a $20.00 target price on the biotechnology company’s stock. B. Riley’s target price would suggest a potential upside of 124.22% from the company’s previous close.
A number of other research analysts have also recently commented on ORMP. HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of Oramed Pharmaceuticals in a research note on Wednesday, November 22nd. ValuEngine raised shares of Oramed Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th.
Oramed Pharmaceuticals (NASDAQ ORMP) traded up $0.38 on Monday, reaching $8.92. The company had a trading volume of 60,623 shares, compared to its average volume of 43,371. Oramed Pharmaceuticals has a fifty-two week low of $5.82 and a fifty-two week high of $11.34.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.
Receive News & Ratings for Oramed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.